Biotech News

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio (ZURA)Zura Bio2026-05-04 20:05 ESTCompany update

HENDERSON, Nev. --(BUSINESS WIRE)--May 4, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

Related news

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

VERAVera Therapeutics2026-07-10 20:05 EST

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFORX4 Pharmaceuticals2026-07-07 20:30 EST

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EQEquillium, Inc.2026-06-02 20:05 EST

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVTXAvalo Therapeutics2026-05-22 20:01 EST

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

HCWBHCW Biologics2026-06-30 12:25 EST

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

HCWBHCW Biologics2026-05-21 13:53 EST

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

INMBINmune Bio2026-07-31 11:00 EST

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

SABSSAB Biotherapeutics2026-07-30 12:30 EST

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

View all latest news

Zura Bio

Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...

Recent company news

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

ZURAZura Bio2026-05-14 11:30 EST

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-05-13 11:30 EST

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-05-04 20:05 EST

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close: 5.71 USD
Market cap: 389.01M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States